Publish in this journal
Journal Information
Vol. 69. Issue 12.
Pages 1233 (December 2016)
Share
Share
Download PDF
More article options
Vol. 69. Issue 12.
Pages 1233 (December 2016)
Letter to the Editor
DOI: 10.1016/j.rec.2016.07.012
Full text access
Predictors of Clinical Outcomes in Patients With Stable Coronary Artery Disease
Predictores de eventos clínicos en pacientes con enfermedad coronaria estable
Visits
...
Mehmet Eyuboglua,
Corresponding author
mhmtybgl@gmail.com

Corresponding author:
, Ugur Kucukb
a Department of Cardiology, Avrupa Medicine Center, Karabaglar, Izmir, Turkey
b Department of Cardiology, Gulhane Military Medical Academy, Haydarpasa Training Hospital, Istanbul, Turkey
Related content
Rev Esp Cardiol. 2016;69:1135-4310.1016/j.rec.2016.04.010
Vasileios F. Panoulas, Hiroyoshi Kawamoto, Katsumasa Sato, Tadashi Miyazaki, Toru Naganuma, Alessandro Sticchi, Azeem Latib, Antonio Colombo
Rev Esp Cardiol. 2016;69:1233-410.1016/j.rec.2016.08.011
Vasileios F. Panoulas, Antonio Colombo
This item has received
...
Visits
(Daily data update)
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor,

We read the article by Panoulas et al.1 with great interest, in which the authors reported the similar 1-year clinical outcomes with ‘Overlapping Bioresorbable Scaffolds’ and ‘New Generation Everolimus-eluting Stents’. The investigators should be congratulated on this interesting study. Nevertheless, we would like to make some points in addition to the findings of the present article. Although percutaneous coronary intervention (PCI) is one of the most important treatments in stable coronary artery disease (CAD), the COURAGE2 investigators demonstrated that PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy in patients with stable CAD. Therefore, optimal medical therapy remains the key point in the treatment of stable CAD regardless of PCI and stent type. In this regard, angiographic success and clinical outcomes should be considered as different topics. Bioresorbable scaffolds and everolimus-eluting stents may have similar angiographic and procedural success. However, when evaluating clinical outcomes, optimal medical therapy including statins, beta-blockers and angiotensin converting enzyme inhibitors should be taken into consideration beyond revascularization and antiplatelet therapy. In the present study by Panoulas et al.,1 there are no clear data on treatment with optimal medical therapy except antiplatelets. Significant differences in the treatment of these medications may affect prognosis and clinical outcomes independently of PCI and the stent types used.

In conclusion, despite similar angiographic and procedural success, prognostic comparison of bioresorbable scaffolds and everolimus-eluting stents requires more comprehensive evaluation. Since optimal medical therapy reduces adverse outcomes independently of PCI in patients with stable CAD, it should be proven that both groups were treated equally with optimal medical therapy including statins, beta-blockers, and angiotensin-converting enzyme inhibitors.

References
[1]
V.F. Panoulas, H. Kawamoto, K. Sato, T. Miyazaki, T. Naganuma, A. Sticchi, et al.
Clinical Outcomes After Implantation of Overlapping Bioresorbable Scaffolds vs New Generation Everolimus Eluting Stents.
[2]
W.E. Boden, R.A. O’Rourke, K.K. Teo, P.M. Hartigan, D.J. Maron, W.J. Kostuk, et al.
COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease.
N Engl J Med., 356 (2007), pp. 1503-1516
Copyright © 2016. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.